MINNEAPOLIS, April 08, 2016 -- On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Guardian II hemostasis valves should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from March 2015 to February 2016 and distributed from April 2015 to February 2016.
The recalled products are specific lots of Model Numbers 8210 and 8211. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 26,550 devices have been manufactured, with 5,283 distributed in the United States. The condition that led to the recall may affect approximately 2.4% of recalled devices.
Vascular Solutions Inc. voluntarily initiated the recall on March 3, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 



